SCHEMBL2588967

SCHEMBL2588967

NC(=O)N(S)c1cc(Cl)ccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
TP53 P04637 3/20 0.41
FSCN1 Q16658 1/20 0.40
TSHR P16473 3/20 0.38
HSD17B10 Q99714 2/20 0.38
CYP3A4 P08684 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
ERCC5 P28715 1/20 0.38
FEN1 P39748 1/20 0.38
RAB9A P51151 1/20 0.37
CASP1 P29466 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPT P10636 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.36
PARP1 P09874 1/20 0.36
SIGMAR1 Q99720 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL653173 0.85 FSCN1 (0.51) ALDH1A1TP53FSCN1TSHRHSD17B10
SCHEMBL4196941 0.82 PARP1 (0.34) ALDH1A1KDM4EPOLBPARP1HPGD
SCHEMBL5539124 0.82 CYP3A4 (0.46) ALDH1A1FSCN1TSHRCYP3A4SMN1; SMN2
SCHEMBL11539989 0.79 ALDH1A1 (0.43) ALDH1A1FSCN1TSHRCYP3A4RAB9A
SCHEMBL4923833 0.78 HTT (0.49) ALDH1A1RAB9AKDM4EMEN1KMT2A
SCHEMBL3265387 0.77 CES2 (0.39) ALDH1A1TSHRHSD17B10KDM4EPOLB
SCHEMBL11363392 0.75 EPHX1 (0.47) ALDH1A1TP53FSCN1HSD17B10ERCC5
SCHEMBL526060 0.72 NPC1 (0.42) ALDH1A1TSHRHSD17B10CYP3A4TDP1
SCHEMBL526256 0.72 TSHR (0.39) ALDH1A1TSHRHSD17B10CYP3A4SMN1; SMN2
SCHEMBL653293 0.70 HTR3E (0.50) ALDH1A1TSHRRAB9ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1926719-B1 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2017-05-31 EP disclosed
US-9388175-B2 2-aniline-4-aryl substituted thiazole derivatives JANSSEN PHARMACEUTICA N.V. (BE) 2016-07-12 US disclosed
US-20110269748-A1 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2011-11-03 US disclosed
EP-1926719-A2 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2008-06-04 EP disclosed
WO-2007031440-A2 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES JANSSEN PHARMACEUTICA N.V. (BE) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110269748-A1 2-ANILINE-4-ARYL SUBSTITUTED THIAZOLE DERIVATIVES CHRNA4, CHRNA5, CHRNA7 ALDH1A1 582/4885TP53 3657/4885FSCN1 4766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.